Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
Dongsheng Yue, Wenxiang Wang, H. Liu, Q. Chen, C. Chen, Lei Liu and 14 more
- Rank
- 60 of 3,853
- Percentile
- top 1.6%
- Where
- Annals of Oncology, 2024
- Citations
- 43
From the 2024 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.